| Autor: |
Naoki Tani, Hideyuki Ikematsu, Takeyuki Goto, Kei Gondo, Yuki Yanagihara, Yasuo Kurata, Ryo Oishi, Junya Minami, Kyoko Onozawa, Sukehisa Nagano, Hiroyuki Kuwano, Koichi Akashi, Nobuyuki Shimono, Yong Chong |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Vaccine: X, Vol 12, Iss , Pp 100224- (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2590-1362 |
| DOI: |
10.1016/j.jvacx.2022.100224 |
| Popis: |
The relation between pre-vaccination antipyretic use and antibody responses to SARS-CoV-2 vaccination has been unclear. We measured the pre- and post-BNT162b2 booster spike-specific IgG titers and recorded antipyretic use and adverse reactions for SARS-CoV-2-naive hospital healthcare workers. The data of 20 cases who used antipyretics within 24 h before vaccination were compared to that of 281 controls. The post-booster geometric mean IgG titers were 15,559 AU/mL (95 % CI, 11,474–21,203) for the cases and 16,850 AU/mL (95 % CI, 15,563–18,243) for the controls (p = 0.622). No significant reduction in the frequency or severity of any of the solicited adverse reactions was found for the cases. Similar results were obtained after adjustment with propensity-score matching for demographic characteristics, baseline IgG titer, and post-vaccination antipyretic use. Antipyretic use within 24 h before vaccination would not affect mRNA COVID-19 vaccine-induced specific antibody responses and that postponement of vaccination due to pre-vaccination antipyretic use would be unnecessary. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
